bioAffinity Technologies, Inc. (BIAFW) stock
BIAFWNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31Also trades as BIAF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 4/3056% below fair value
$0.24+0.00 (0.00%)
Close on Oct 30, 2026Market cap $23.58MP/E –Yield –
bioAffinity Technologies operating margin
Operating margin is operating income as a percentage of revenue.
bioAffinity Technologies's operating margin for the twelve months ending Jun 30, 2026 was -209.8%. For fiscal 2025 it was -171.6%, against -95.6% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -171.6% | −75.9 |
| FY2024 | Dec 31, 2024 | -95.6% | +219.2 |
| FY2023 | Dec 31, 2023 | -314.8% | −256.7 |
| FY2022 | Dec 31, 2022 | -58.1% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -220.8% | −22.6 |
| Q1 FY2026 | Mar 31, 2026 | -267.6% | −125.9 |
| Q4 FY2025 | Dec 31, 2025 | -196.9% | −63.5 |
| Q3 FY2025 | Sep 30, 2025 | -158.6% | −74.6 |
| Q2 FY2025 | Jun 30, 2025 | -198.2% | −111.1 |
| Q1 FY2025 | Mar 31, 2025 | -141.7% | −60.9 |
| Q4 FY2024 | Dec 31, 2024 | -133.5% | −29.9 |
| Q3 FY2024 | Sep 30, 2024 | -84.0% | +684.7 |
| Q2 FY2024 | Jun 30, 2024 | -87.1% | +8922.7 |
| Q1 FY2024 | Mar 31, 2024 | -80.8% | +5.4 |
| Q4 FY2023 | Dec 31, 2023 | -103.6% | −80.1 |
| Q3 FY2023 | Sep 30, 2023 | -768.7% | +84114.4 |
| Q2 FY2023 | Jun 30, 2023 | -9009.8% | +43373.0 |
| Q1 FY2023 | Mar 31, 2023 | -86.3% | – |
| Q4 FY2022 | Dec 31, 2022 | -23.5% | – |
| Q3 FY2022 | Sep 30, 2022 | -84883.1% | – |
| Q2 FY2022 | Jun 30, 2022 | -52382.8% | – |